Company / Cash & Equivalents
Insight Molecular Diagnostics Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$11.6M
FY2025
5-year range
$8.6M / $35.6M
FY2021-FY2025
Trend
+34.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $12M.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of +10.2%.
Improved from $9M to $12M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -16.6%
- 5-Year CAGR
- +10.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +10.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 34.1% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.6M | +34.1% |
| FY2024 | $8.6M | -8.4% |
| FY2023 | $9.4M | -52.8% |
| FY2022 | $20.0M | -43.8% |
| FY2021 | $35.6M | +398.5% |
| FY2020 | $7.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026